Compile Data Set for Download or QSAR
Report error Found 75 Enz. Inhib. hit(s) with all data for entry = 10119
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514601(US11098029, Example 37)
Affinity DataIC50: 0.230nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514590(US11098029, Example 26)
Affinity DataIC50: 0.230nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514589(US11098029, Example 25)
Affinity DataIC50: 0.270nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514632(US11098029, Example 67)
Affinity DataIC50: 0.460nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514585(US11098029, Example 21)
Affinity DataIC50: 0.470nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514580(US11098029, Example 16)
Affinity DataIC50: 0.5nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514582(US11098029, Example 18)
Affinity DataIC50: 0.5nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514583(US11098029, Example 19)
Affinity DataIC50: 0.5nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514596(US11098029, Example 32)
Affinity DataIC50: 0.520nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514581(US11098029, Example 17)
Affinity DataIC50: 0.530nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514618(US11098029, Example 53)
Affinity DataIC50: 0.600nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514586(US11098029, Example 22)
Affinity DataIC50: 0.660nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514616(US11098029, Example 51)
Affinity DataIC50: 0.700nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514619(US11098029, Example 54)
Affinity DataIC50: 0.700nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514599(US11098029, Example 36 | US11098029, Example 35)
Affinity DataIC50: 0.760nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514636(US11098029, Example 71)
Affinity DataIC50: 0.760nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514621(US11098029, Example 56)
Affinity DataIC50: 0.800nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514587(US11098029, Example 23)
Affinity DataIC50: 0.920nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514590(US11098029, Example 26)
Affinity DataIC50: 0.920nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514593(US11098029, Example 29)
Affinity DataIC50: 0.930nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514588(US11098029, Example 24)
Affinity DataIC50: 1nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514624(US11098029, Example 59)
Affinity DataIC50: 1nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514592(US11098029, Example 28)
Affinity DataIC50: 1.07nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514628(US11098029, Example 63)
Affinity DataIC50: 1.10nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514604(US11098029, Example 39)
Affinity DataIC50: 1.15nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514620(US11098029, Example 55)
Affinity DataIC50: 1.20nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514627(US11098029, Example 62)
Affinity DataIC50: 1.40nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514622(US11098029, Example 57)
Affinity DataIC50: 1.60nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514584(US11098029, Example 20)
Affinity DataIC50: 1.67nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514623(US11098029, Example 58)
Affinity DataIC50: 1.80nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514577(US11098029, Example 13)
Affinity DataIC50: 1.90nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514630(US11098029, Example 65)
Affinity DataIC50: 2.20nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514578(US11098029, Example 14)
Affinity DataIC50: 2.5nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514611(US11098029, Example 46)
Affinity DataIC50: 3nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514579(US11098029, Example 15)
Affinity DataIC50: 3.18nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514595(US11098029, Example 31)
Affinity DataIC50: 3.63nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514605(US11098029, Example 41 | US11098029, Example 40)
Affinity DataIC50: 4.56nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514626(US11098029, Example 61)
Affinity DataIC50: 4.60nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514625(US11098029, Example 60)
Affinity DataIC50: 5.20nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514614(US11098029, Example 49)
Affinity DataIC50: 5.5nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514591(US11098029, Example 27)
Affinity DataIC50: 6.82nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514603(US11098029, Example 38)
Affinity DataIC50: 7.07nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514617(US11098029, Example 52)
Affinity DataIC50: 7.80nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514608(US11098029, Example 43)
Affinity DataIC50: 8.10nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514633(US11098029, Example 68)
Affinity DataIC50: 8.30nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514573(US11098029, Example 9)
Affinity DataIC50: 8.57nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514613(US11098029, Example 48)
Affinity DataIC50: 9.40nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514572(US11098029, Example 8)
Affinity DataIC50: 9.52nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514594(US11098029, Example 30)
Affinity DataIC50: 10.8nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM514629(US11098029, Example 64)
Affinity DataIC50: 12.5nMAssay Description:In a typical experiment, the OX1 and OX2 receptor agonist activity is determined in accordance with the following general experimental method. Chines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

Displayed 1 to 50 (of 75 total ) | Next | Last >>
Jump to: